Unmatched Evidence

Cook Medical

Two decades of evidence, including over 30 peer-reviewed studies and meta-analyses, confirm that minocycline and rifampin (M+R) catheters are an effective tool to provide broad-spectrum protections against gram-positive and gram-negative infections for both short- and long-term use.

Process Plus Antimicrobial Catheter Technology

People Chart

Cook Spectrum peer-reviewed evidence

The efficacy of Cook Spectrum technology is supported by more than 30 published sources, including four systematic reviews and meta-analyses3, 4, 5, 6 and seven prospective randomized studies,2, 7, 8, 9, 10, 11, 12 — the highest quality and most powerful levels on the "strength of evidence" pyramid.

Strength of Evidence Pyramid
References – Unmatched Evidence
  1. Bonne S, Mazuski J, Sona C, et al. Effectiveness of minocycline and rifampin vs chlorhexidine and silver sulfadiazine-impregnated central venous catheters in preventing central line-associated bloodstream infection in a high-volume academic intensive care unit: a before and after trial. J Am Coll Surg. 2015;221(3):739–747.
  2. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med. 1999;340(1):1–8.
  3. Casey AL, Mermel LA, Nightingale P, et al. Antimicrobial central venous catheters in adults: a systematic review and meta-analysis. Lancet Infec Dis. 2008;8(12):763-776.
  4. Wang H, Huang T, Jing J, et al. Effectiveness of different central venous catheters for catheter-related infections: a network meta-analysis. J Hosp Infect. 2010;76(1):1–11.
  5. Ramritu P, Halton K, Collignon P, et al. A systematic review comparing the relative effectiveness of antimicrobial-coated catheters in intensive care units. Am J Infect Control. 2008;36(2):104-117.
  6. Falagas M, Fragoulis K, Bliziotis IA, et al. Rifampin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007;59(3):359–369.
  7. León C, Ruiz-Santana S, Rello J, et al. Benefits of minocycline and rifampin-impregnated central venous catheters: a prospective, randomized, double-blind, controlled, multicenter trial. Intensive Care Med. 2004;30(10):1891–1899.
  8. Fraenkel D, Rickard C, Thomas P, et al. A prospective, randomized trial of rifampin-minocycline-coated and silver-platinum-carbon-impregnated central venous catheters. Crit Care Med. 2006;34(3):668–675. 
  9. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial. Ann Intern Med. 1997;127(4):267–274. 
  10. Marik PE, Abraham G, Careau P, et al. The ex vivo antimicrobial activity and colonization rate of two antimicrobial-bonded central venous catheters. Crit Care Med. 1999;27(6):1128–1131.
  11. Darouiche RO, Berger DH, Khardori N, et al. Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized controlled trial. Ann Surg. 2005;242(2):193–200.
  12. Hanna H, Benjamin R, Chatzinikolaou I, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol. 2004;22(15):3163-3171.